

AMENDMENTS TO THE CLAIMS

Please cancel claims 13, 14, 35, 36, 38-42, 48, 49, 59, 62, and 78-96 without prejudice to Applicant's right to present these claims in a later-filed amendment.

1. **(Original)** A regulated polymerase III expression system, comprising
 - (a) a first nucleic acid segment comprising a regulated promoter operably linked to a first element encoding a transcription factor; and
 - (b) a second nucleic acid segment comprising a recombinant polymerase III promoter regulated by the transcription factor,wherein the transcription factor increases transcription from the recombinant polymerase III promoter.
2. **(Original)** The expression system of claim 1, wherein binding of the transcription factor to (i) the polymerase III promoter or to (ii) at least one binding site operably linked to the polymerase III promoter increases transcription from the recombinant polymerase III promoter.
3. **(Original)** The expression system of claim 1, wherein the first and second nucleic acid segments reside in the same nucleic acid.
4. **(Original)** A nucleic acid comprising the first and second nucleic acid segments of claim 1.
5. **(Original)** The nucleic acid of the preceding claim comprising the nucleic acid sequence as set forth in SEQ ID NO: 1.
6. **(Original)** A nucleic acid comprising the nucleic acid sequence as set forth in SEQ ID NO: 1.
7. **(Original)** A nucleic acid comprising the nucleic acid sequence as set forth in SEQ ID NO: 2.

8. **(Original)** A cell comprising the regulated polymerase III expression system of claim 1.
9. **(Original)** A non human organism comprising the cell of claim 8.
10. **(Original)** A non human organism comprising the regulated polymerase III expression system of claim 1.
11. **(Original)** The expression system of the claim 1, wherein the regulated promoter is an inducible promoter.
12. **(Original)** The expression system of claim 11, wherein transcription from the inducible promoter is increased in the presence of an ecdysone, an ecdysone-analog or an ecdysone mimic.
- 13-14. **(Canceled)**
15. **(Original)** The expression system of claim 1, wherein transcription from the regulated promoter is developmentally regulated.
16. **(Original)** The expression system of the claim 1, wherein transcription from the regulated promoter is tissue specific.
17. **(Original)** The expression system of the claim 1, wherein transcription from the regulated promoter is temporally regulated.
18. **(Original)** The expression system of the claim 1, wherein transcription from the regulated promoter is cell-cycle regulated.
19. **(Original)** The expression system of claim 1, wherein the regulated promoter comprises or is operably linked to at least one ecdysone response element.
20. **(Original)** The expression system of claim 1, wherein the transcription factor comprises

a DNA-binding domain and a transactivating domain.

21. **(Original)** The expression system of the preceding claim, wherein the DNA-binding domain is a GAL4 DNA-binding domain.
22. **(Original)** The expression system of claim 1, wherein the DNA-binding domain does not comprise a tet DNA-binding domain.
23. **(Original)** The expression system of claim 20, wherein the transactivating domain is an Oct-1 or an Oct-2 domain.
24. **(Original)** The expression system of claim 20, wherein the transactivating domain is an Oct-2^Q(Q→A) domain.
25. **(Original)** The expression system of claim 20, wherein the transcription factor binds to at least one binding site operably linked to the polymerase III promoter.
26. **(Original)** The expression system of claim 1, wherein the transcription factor does not bind an inducer.
27. **(Original)** The expression system of the preceding claim, wherein the inducer is tetracycline or doxycycline.
28. **(Original)** The expression system of claim 1, wherein expression of the transcription factor is dependent on the presence of an inducer.
29. **(Original)** The expression system of claim 1, wherein transcription from the recombinant polymerase III promoter is dependent on the presence of an inducer.
30. **(Original)** The expression system of the preceding claim, wherein the transcription factor regulates transcription from the recombinant RNA polymerase III promoter by binding to (i) at least one binding site operably linked to said promoter; or (ii) to said

promoter.

31. **(Original)** The expression system of the preceding claim, wherein binding of the transcription factor to the recombinant RNA polymerase promoter by or to a binding site operably linked to said promoter increases transcription from said promoter.
32. **(Original)** The method of claim 29, wherein binding affinity of the transcription factor for (i) the polymerase III promoter or for (ii) the binding site operably linked to said promoter is substantially the same in the presence or absence of the inducer.
33. **(Original)** The expression system of claim 1, wherein the polymerase III promoter is a mammalian promoter.
34. **(Original)** The expression system of claim 1, wherein the polymerase III promoter element comprises a U6 promoter or an H1 promoter.
- 35-36. **(Canceled)**
37. **(Original)** The expression system of claim 1, wherein the second nucleic acid segment comprises at least one binding site for the transcription factor operably linked to the recombinant polymerase III promoter.
- 38-42. **(Canceled)**
43. **(Original)** The expression system of claim 1, wherein the regulated promoter is further operably linked to a second element.
44. **(Original)** The expression system of the preceding claim, wherein the second element encodes a reporter protein, a selectable marker or an enzyme.
45. **(Original)** The expression system of the preceding claim, wherein the reporter protein comprises a fluorescent protein.

46. **(Original)** The expression system of the preceding claim, wherein the fluorescent protein comprises a GFP protein.
47. **(Original)** The expression system of the preceding claim, wherein the selectable marker comprises a cell surface receptor or a drug-resistance marker.
- 48-49. **(Canceled)**
50. **(Original)** The expression system of claim 1, further comprising a sequence of a transgene operably linked to the recombinant polymerase III promoter.
51. **(Original)** The expression system of claim 50, wherein the transgene encodes a non-coding RNA.
52. **(Original)** The expression system of claim 51, wherein the non-coding RNA comprises an siRNA.
53. **(Original)** The expression system of claim 51, wherein the transgene comprises a hairpin RNA.
54. **(Original)** The expression system of claim 51, wherein the transgene comprises a ribozyme.
55. **(Canceled)**
56. **(Original)** The expression system of claim 51, wherein the non-coding RNA inhibits the expression of an essential gene.
57. **(Original)** The expression system of claim 1, further comprising a cloning site downstream of the polymerase III promoter.
58. **(Original)** The expression system of the preceding claim, wherein the cloning site

comprises a restriction enzyme recognition site or a ccdB sequence.

59. **(Canceled)**
60. **(Original)** The expression system of claim 1, comprising at least one nucleic acid segment encoding a regulatory protein which promotes transcription from the regulated promoter.
61. **(Original)** The expression system of the preceding claim, comprising a nucleic acid segment encoding two regulatory proteins which promote transcription from the regulated promoter.
62. **(Canceled)**
63. **(Original)** The expression system of claim 60, wherein the regulatory protein binds to an inducer.
64. **(Original)** The expression system of the preceding claim, wherein binding of the regulatory protein to the inducer promotes transcription from the regulated promoter.
65. **(Original)** The expression system of the claim 63, wherein binding of the regulatory protein to the inducer promotes binding of the regulatory protein to a response element.
66. **(Original)** The expression system of claim 60, wherein the regulatory protein binds to the regulated promoter or to a response element operably linked to the regulated promoter.
67. **(Original)** The expression system of the preceding claim, wherein binding of the regulatory protein to the regulated promoter or to a response element operably linked to the regulated promoter promotes transcription from the regulated promoter.
68. **(Original)** The expression system of claim 60, wherein the regulatory protein does not

bind to the polymerase III promoter.

69. **(Original)** The expression system of claim 60, wherein the regulatory protein comprises a DNA binding domain.
70. **(Original)** The expression system of the preceding claim, wherein the DNA-binding domain of the regulatory protein comprises a tet repressor DNA binding domain, an RxR DNA binding domain or a nuclear hormone receptor DNA binding domain.
71. **(Original)** The expression system of claim 60, wherein the regulatory protein promotes transcription from the regulated promoter upon binding to an inducer.
72. **(Original)** The expression system of the preceding claim, wherein the inducer is tetracycline, ecdysone hormone, or an agonist thereof.
73. **(Original)** The expression system of claim 60, wherein the protein is a nuclear receptor or a transcription factor..
74. **(Original)** The expression system of the preceding claim, wherein the protein comprises a VgEcR or an RXR protein.
75. **(Original)** A method of reducing gene expression of a gene in a cell, the method comprising
- (a) providing a cell comprising
 - (i) a regulated promoter operably linked to a first element encoding a transcription factor; and
 - (ii) a recombinant polymerase III promoter regulated by the transcription factor and operably linked to a coding sequence for an RNA molecule, wherein expression of the RNA molecule reduces expression of the gene; and
 - (b) contacting the cell with an inducer, wherein the inducer promotes transcription of the RNA molecule from the recombinant polymerase III promoter, thereby reducing expression of the gene in the cell.

76. **(Original)** A method of determining the effects of reducing gene expression of a gene in a cell, the method comprising
- (a) providing a cell comprising
 - (i) a regulated promoter operably linked to a first element encoding a transcription factor; and
 - (ii) a recombinant polymerase III promoter regulated by the transcription factor and operably linked to a coding sequence for an RNA molecule, wherein expression of the RNA molecule reduces expression of the gene;
 - (b) subjecting the cell to a condition which promotes transcription of the RNA molecule from the recombinant polymerase III promoter; and
 - (c) determining the phenotype of the cell;
- thereby determining the effects of reducing expression of the gene.
77. **(Original)** A method of determining the effects of reducing gene expression of a gene in an organism, the method comprising
- (a) providing an organism wherein at least a cell in the organism comprises
 - (i) a regulated promoter operably linked to a first element encoding a transcription factor; and
 - (ii) a recombinant polymerase III promoter regulated by the transcription factor and operably linked to a coding sequence for an RNA molecule, wherein expression of the RNA molecule reduces expression of the gene;
 - (b) subjecting the organism to conditions which promote transcription of the RNA molecule from the recombinant polymerase III promoter in at least one cell; and
 - (c) determining the phenotype of at least one cell in the organism;
- thereby determining the effects of silencing expression of a gene in an organism.

78-96. **(Canceled)**